FDA Requires Postsafety Trials for Long-Acting Beta-Agonists : Internal Medicine News
Links shared publicly online about this topic.
- 355total visits
FDA Requires Postsafety Trials for Long-Acting Beta-Agonists : Internal Medicine News
Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre
View full resource at internalmedicinenews.com
Tags: Asthma Medication, COPD Medication, Clinical Trial, FDA, Advair, Symbicort, Dulera, Medical
Most Recently Shared on April 18, 2011 at 9:14 pm By:
FDA demanding mfrs conduct 5 large clinical trials for Symbicort, Advair Diskus, Dulera, & Foradil. M. Dales reports. http://bit.ly/gXm3hf
Advertisement
